Literature DB >> 6300994

Sendai-virus-induced cell-mediated cytotoxicity in vitro. The role of viral glycoproteins in cell-mediated cytotoxicity.

A Alsheikhly, C Orvell, B Härfast, T Andersson, P Perlmann, E Norrby.   

Abstract

Treatment of peripheral blood lymphocytes from normal donors with small amounts of purified Sendai virions results in enhanced cellular cytotoxicity in vitro to uninfected tissue culture target cells (virus-dependent cellular cytotoxicity (VDCC)), without any obvious correlation to the natural cytotoxicity (NK) displayed by the lymphocytes in the absence of virus. Removal from the virions of the two surface components present in the viral envelope, the HN glycoprotein (gp 71), carrying haemagglutinating and neuraminidase activity, and the F glycoprotein (gp 49), carrying fusion activity, by treatment with pronase abrogated their capacity to induce VDCC. Similar results were obtained when virions lacking the HN glycoprotein after treatment with chymotrypsin were added to the lymphocytes. In contrast, treatment of the virus particles with trypsin, which removed the F glycoprotein, did not affect their capacity to induce VDCC. When the solubilized and separated peplomers were used for lymphocyte treatment, either alone or in combination, the purified HN glycoprotein had full capacity to induce VDCC, whereas the F glycoprotein was inactive. These results suggest that the HM peplomer is solely or primarily responsible for the cytolytic activity arising in non-sensitized lymphocytes when confronted with certain viruses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300994     DOI: 10.1111/j.1365-3083.1983.tb00775.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Characterization with monoclonal antibodies of human lymphocytes active in natural killing and antibody-dependent cell-mediated cytotoxicity of dengue virus-infected cells.

Authors:  I Kurane; D Hebblewaite; F A Ennis
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

2.  A protease activation mutant, MVCES1, as a safe and potent live vaccine derived from currently prevailing Sendai virus.

Authors:  X L Wang; M Itoh; H Hotta; M Homma
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

3.  In vitro enhancement of human natural cell-mediated cytotoxicity by purified influenza virus glycoproteins.

Authors:  D J Arora; M Houde; D M Justewicz; R Mandeville
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

4.  Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells.

Authors:  Henry Ogbomo; Martin Michaelis; Janina Geiler; Marijke van Rikxoort; Thomas Muster; Andrej Egorov; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2009-12-15       Impact factor: 3.402

5.  Oxygen uptake associated with Sendai-virus-stimulated chemiluminescence in rat thymocytes contains a significant non-mitochondrial component.

Authors:  M E Kolbuch-Braddon; E Peterhans; R Stocker; M J Weidemann
Journal:  Biochem J       Date:  1984-09-01       Impact factor: 3.857

6.  Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus.

Authors:  M Tashiro; Y Fujii; K Nakamura; M Homma
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  Inhibition of transmissible gastroenteritis coronavirus (TGEV) multiplication in vitro by non-immune lymphocytes.

Authors:  B Charley; H Laude; C La Bonnardière
Journal:  Ann Inst Pasteur Virol       Date:  2009-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.